Arşiv logosu
  • English
  • Türkçe
  • Giriş
    Yeni kullanıcı mısınız? Kayıt için tıklayın. Şifrenizi mi unuttunuz?
Arşiv logosu
  • Koleksiyonlar
  • Sistem İçeriği
  • Analiz
  • Talep/Soru
  • English
  • Türkçe
  • Giriş
    Yeni kullanıcı mısınız? Kayıt için tıklayın. Şifrenizi mi unuttunuz?
  1. Ana Sayfa
  2. Yazara Göre Listele

Yazar "Ahsan, Mohamed Jawed" seçeneğine göre listele

Listeleniyor 1 - 1 / 1
Sayfa Başına Sonuç
Sıralama seçenekleri
  • Küçük Resim Yok
    Öğe
    Design, synthesis and anti-hyperglycemic assessments of novel 5-benzyli-denethiazolidine-2,4-dione derivatives as PPAR-? agonist
    (Elsevier, 2023) Ali, Amena; Ali, Abuzer; Asati, Vivek; Kaya, Savas; Ahsan, Mohamed Jawed
    The treatment of diabetes mellitus still relies predominantly on peroxisome proliferator-activated receptor-gamma (PPAR-gamma) therapy, known for its effectiveness. In this present study, a novel series of benzylidene-linked thia-zolidine-2,4-dione compounds was conceptualized, synthesized, and subjected to assessment for their potential antidiabetic properties. Notably, among the compounds examined, 5-((Z)-4-(((E)-Propylidene)amino)benzyli-dene)thiazolidine-2,4-dione, designated as 4c, emerged as the most promising candidate, exhibiting the highest PPAR-gamma agonistic activity with an EC50 value of 0.35 +/- 0.52 mu M. Additionally, molecular docking investigations were conducted on twelve 2,4-thiazolidinedione compounds, with a pyrazole moiety incorporated, within the ligand binding domain of PPAR-gamma. Compound 4c, in particular, demonstrated a Glide XP score of-9.104, sur-passing the score of the crystal ligand (Glide XP score =-7.482). Notably, both exhibited similar interactions with key amino acids, including HIE323, SER289, and GLN286. Furthermore, three derivatives (4a-c) with promising PPAR-gamma agonistic activity and favorable molecular docking scores underwent in vivo evaluation for their capacity to lower blood glucose levels using a streptozotocin-induced diabetic mice model. In comparison to the reference drug pioglitazone, Compound 4c displayed commendable in-vivo performance across multiple parameters, encompassing serum HDL, serum LDL, serum total cholesterol, and serum triglyceride levels. Mo-lecular dynamics simulations provided insights into the impact of ligand 4c, indicating its role in enhancing protein stability and rigidity. These findings emphasize its potential as a potent protein inhibitor, thus opening novel avenues for the intelligent design of molecules with high efficacy in the management of hyperglycemia.

| Sivas Cumhuriyet Üniversitesi | Kütüphane | Açık Erişim Politikası | Rehber | OAI-PMH |

Bu site Creative Commons Alıntı-Gayri Ticari-Türetilemez 4.0 Uluslararası Lisansı ile korunmaktadır.


Kütüphane ve Dokümantasyon Daire Başkanlığı, Sivas, TÜRKİYE
İçerikte herhangi bir hata görürseniz lütfen bize bildirin

DSpace 7.6.1, Powered by İdeal DSpace

DSpace yazılımı telif hakkı © 2002-2025 LYRASIS

  • Çerez Ayarları
  • Gizlilik Politikası
  • Son Kullanıcı Sözleşmesi
  • Geri Bildirim